Datasheet for ABIN5668226

Recombinant anti-ErbB2/Her2 (Trastuzumab Biosimilar) antibody

1 Publication

Go to Product page

Overview

Quantity:	200 µg
Target:	ErbB2/Her2 (Trastuzumab Biosimilar)
Reactivity:	Human
Host:	Human
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This ErbB2/Her2 (Trastuzumab Biosimilar) antibody is un-conjugated
Application:	ELISA, Flow Cytometry (FACS), Immunohistochemistry (IHC)

Product Details

Immunogen:	A431 cells (human epidermoid carcinoma) (over)expressing EGFR.
Clone:	4D5-8
Isotype:	IgG1 kappa
Specificity:	Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30 % of invasive breast cancers and 70 % of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder.
Characteristics:	OriginalSpeciesName: Human OriginalFormat: IgG1
Purification:	Purified antibody.

Product Details

Purity:	> 98 % as determined by SDS-PAGE
Endotoxin Level:	Endotoxin is < 1.0 EU/mg as determined by the LAL method

Target Details

Target:	ErbB2/Her2 (Trastuzumab Biosimilar)
Abstract:	ErbB2/Her2 (Trastuzumab Biosimilar) Products
Target Type:	Biosimilar
Background:	CD340, Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, p185HER2, EGFR
UniProt:	P04626

Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Comment:	NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
Restrictions:	For Research Use only

Handling

Buffer:	PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Publications

Product cited in:	Maisel, Broka, Atwell, Bunch, Kupp, Singh, Mehta, Schroeder: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: **Journal of translational medicine**, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).